Monograph

C09CA04 - Irbesartan

Propably not porphyrinogenic

Rationale

Substrate for CYP 2C9. Occasional clinical experience of non-porphyrinogenicity.

Chemical description

Angiotensin II receptor antagonist. Biovailability 60 - 80 %; metabolized by CYP 2C9. Less potent inhibitor of CYPs 1A2, 2C9, 3A4. Thunell, patient report (n=1): tolerated. Andersson, patient report (n=1): tolerated French list: avoid.

IPNet drug reports

Uneventful use reported in 10 patients with acute porphyria.

Similar drugs

Explore alternative drugs in similar therapeutic classes C09C / C09CA or go back.

Tradenames

This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Show more details and information about the listed tradenames